- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.02. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.01. | Lexeo Therapeutics stellt Führungsteam neu auf und ernennt Chief Medical Officer | - | Investing.com Deutsch | ||
| 27.01. | Lexeo Therapeutics announces key leadership appointments | 1 | Investing.com | ||
| 27.01. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.01. | Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock | 5 | Investing.com | ||
| 13.01. | Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating | 1 | Investing.com | ||
| 13.01. | H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns | 1 | Investing.com | ||
| 12.01. | Aktie von Lexeo Therapeutics bricht nach Studiendaten zur Gentherapie ein | 5 | Investing.com Deutsch | ||
| 12.01. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.01. | Lexeo: Positive Studiendaten zu Gentherapie bei Herzerkrankung | 3 | Investing.com Deutsch | ||
| 12.01. | Lexeo's gene therapy shows promising results for heart condition | 3 | Investing.com | ||
| 12.01. | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | 176 | GlobeNewswire (Europe) | LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants... ► Artikel lesen | |
| 08.01. | Lexeo Therapeutics Partners With JNJ To Investigate Localized Cardiac Delivery Of Gene Therapy | 417 | AFX News | NEW BRUNSWICK (dpa-AFX) - Lexeo Therapeutics, Inc. (LXEO), Thursday announced a research collaboration with Johnson & Johnson (JNJ) to investigate localized cardiac delivery of gene therapy.Under... ► Artikel lesen | |
| 08.01. | Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy | 189 | GlobeNewswire (Europe) | Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies, including Impella heart pumps... ► Artikel lesen | |
| 27.12.25 | Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline | 3 | Insider Monkey | ||
| 17.12.25 | Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating | 3 | Investing.com | ||
| 10.12.25 | Lexeo Therapeutics stock holds Overweight rating as Cantor sees PKP2-ACM potential | 1 | Investing.com | ||
| 10.12.25 | Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock | 1 | Investing.com | ||
| 01.12.25 | Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target | 2 | Investing.com | ||
| 01.12.25 | Cantor Fitzgerald stuft Lexeo Therapeutics als unterbewertet ein und bestätigt Kursziel von 19 $ | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,805 | -1,28 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen bei unverändertem Kursziel von 54 US-Dollar von "Hold" auf "Buy" hochgestuft. Analyst Jan Koch kehrt nach seiner Abstufung im Januar... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,960 | -2,63 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma erhält Meilensteinzahlung des Partners Huadong für klinische Studie mit HDP-101 in China | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma erhält Meilensteinzahlung des Partners Huadong für klinische Studie mit HDP-101 in China
18.03.2026... ► Artikel lesen | |
| ILLUMINA | 107,32 | -0,24 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| BRAIN BIOTECH | 2,300 | -1,71 % | BRAIN Biotech AG - Ruhe im Kursrückgang bewahren | ||
| SANGAMO THERAPEUTICS | 0,288 | +0,88 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,404 | -2,87 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| VAXART | 0,410 | 0,00 % | Vaxart signals $700M COVID-19 vaccine milestone path as Sanofi partnership advances and 2026 data readouts approach | ||
| EMERGENT BIOSOLUTIONS | 6,892 | -2,68 % | Morning Market Movers: Neurogene, Duolingo, Xponential Fitness, Emergent BioSolutions See Big Swings | WASHINGTON (dpa-AFX) - At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| DENALI THERAPEUTICS | 17,375 | +1,64 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary... ► Artikel lesen | |
| TRAWS PHARMA | 2,130 | +0,95 % | Traws Pharma, Inc.: Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal ... | Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID- with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution... ► Artikel lesen | |
| UNIQURE | 13,755 | -1,43 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| CAPRICOR | 25,100 | -1,18 % | CAPRICOR THERAPEUTICS, INC. - 10-K, Annual Report | ||
| AVID BIOSERVICES | - | - | Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California | COSTA MESA, Calif., Feb. 24, 2026 /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state... ► Artikel lesen | |
| CORMEDIX | 5,400 | -0,92 % | CorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled... ► Artikel lesen | |
| REGENXBIO | 7,000 | -0,71 % | Regenxbio, Solid report data with Duchenne gene therapies |
Das Unternehmen LEXEO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,99 % bei einem Aktienkurs von 5,665 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.